1. Home
  2. NOM vs NEUP Comparison

NOM vs NEUP Comparison

Compare NOM & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Missouri Quality Municipal Income Fund

NOM

Nuveen Missouri Quality Municipal Income Fund

N/A

Current Price

$11.42

Market Cap

26.7M

Sector

Finance

ML Signal

N/A

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$3.98

Market Cap

21.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOM
NEUP
Founded
1993
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
26.7M
21.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NOM
NEUP
Price
$11.42
$3.98
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
6.9K
45.4K
Earning Date
01-01-0001
02-13-2026
Dividend Yield
3.39%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$15,649,448.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.52
$3.65
52 Week High
$10.48
$21.40

Technical Indicators

Market Signals
Indicator
NOM
NEUP
Relative Strength Index (RSI) 48.03 44.45
Support Level $10.99 $3.98
Resistance Level $11.85 $4.18
Average True Range (ATR) 0.31 0.14
MACD 0.01 0.01
Stochastic Oscillator 43.00 13.79

Price Performance

Historical Comparison
NOM
NEUP

About NOM Nuveen Missouri Quality Municipal Income Fund

Nuveen Missouri Quality Municipal Income Fund is a diversified, closed-end management investment company operating in the United States. The Fund's investment objective is current income exempt from both regular federal income taxes and Missouri personal income taxes, and to enhance portfolio value relative to the Missouri municipal bond market by investing in tax-exempt Missouri municipal obligations that are underrated or undervalued or that represent municipal market sectors that are undervalued. The fund invests in municipal securities as well as floating rate securities, and derivatives such as futures, options, and swap contracts to the necessary extent.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: